Table 4.
Effect of high altitude exposure on the antero-posterior sway velocity: multivariable regression.
| Dependent variable: AP sway velocity, cm/s | |||
|---|---|---|---|
| R2 entire model = 0.180 P < 0.001 | Coefficient | [95% CI] | P-Value |
| Altitude (1 = 760 m; 2 = 3100 m) | 0.048 | 0.009 to 0.087 | 0.016 |
| Drug (1 = Plc; 2 = Dex) | 0.006 | -0.104 to 0.116 | 0.915 |
| Age, years | 0.011 | 0.004 to 0.018 | 0.001 |
| Sex (1 = men; 2 = women) | -0.037 | -0.231 to 0.157 | 0.708 |
| Height, cm | 0.012 | 0.003 to 0.020 | 0.009 |
| FEV1, % pred | -0.003 | -0.007 to 0.000 | 0.078 |
| AMS (1 = No; 2 = Yes) | 0.099 | -0.014 to 0.212 | 0.085 |
| Intercept | -1.577 | -3.385 to 0.230 | 0.087 |
Plc, Placebo; Dex, Dexamethasone; FEV1, % pred., Forced expiratory volume in 1 second in % of the predicted FEV1; AMS, development of acute mountain sickness during altitude exposure assessed by the environmental symptoms score ≥0.7.